FDA accepts CMC plan for lead Bionovo drug

The FDA has accepted Bionovo's chemistry, manufacturing and controls (CMC) plan for its lead drug candidate, Menerba. With the FDA's approval of the company's CMC plan, Bionovo is now in final discussions with the agency to complete the design of the Phase III pivotal trials in the U.S. Bionovo release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.